ACC.24 - Brian Bergmark discusses the results of the BRIDGE-TIMI 73a trial in patients with either moderate hypertriglyceridemia and elevated CV risk or with severe hypertriglyceridemia. “Olezarsen reduced triglycerides levels to an extent that is greater than currently available drugs”.
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
Restart
Resume
Transcript
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
closeShare this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Brian Bergmark, MD is an Associate Physician in Interventional Cardiology in the Division of Cardiovascular Medicine at the Brigham and Women's Hospital, Boston, MA, US. He also is an Assistant Professor of Medicine at Harvard Medical School in Boston, MA, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in N Engl J Med.
Release date: 8 april 2024
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
ACC.24 - Brian Bergmark discusses the results of the BRIDGE-TIMI 73a trial in patients with either moderate hypertriglyceridemia and elevated CV risk or with severe hypertriglyceridemia. “Olezarsen reduced triglycerides levels to an extent that is greater than currently available drugs”.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Brian Bergmark, MD is an Associate Physician in Interventional Cardiology in the Division of Cardiovascular Medicine at the Brigham and Women's Hospital, Boston, MA, US. He also is an Assistant Professor of Medicine at Harvard Medical School in Boston, MA, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in N Engl J Med.
Release date: 8 april 2024
Presenters
Facebook Comments